Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours

Conclusion Although data from randomised clinical trials on the clinical impact of sunitinib TDM are lacking, our findings support implementation of sunitinib TDM in clinical practice. For rare cancers with well-defined exposure–response relationships, modelling and simulation might allow the optimisation of dosing strategies when clinical trials cannot be performed due to low number of patients.

http://link.springer.com/10.1007/s00280-016-3071-1

Source: Cancer Chemotherapy and Pharmacology - June 12, 2016 Category: Cancer & Oncology Source Type: research